Nicoletta Colombo

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Domenica Lorusso, Yang Xiang, Kosei Hasegawa et al. · The Lancet · 2024 · 161 citations

Medicine, Oncology, Pharmacotherapy +12

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · The Lancet Oncology · 2021 · 149 citations

Medicine, Gynecology, Oncology +15

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 86 citations · Full text

Medicine, Gynecology, Oncology +11

Building clinical trials around patients: Evaluation and comparison of decentralized and conventional site models in patients with low back pain

Carsten Sommer, Diego Zuccolin, Valdo Arnera et al. · Contemporary Clinical Trials Communications · 2018 · 70 citations · Full text

Medicine, Physical Medicine, Pain Management +16

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Krishnansu S. Tewari, Nicoletta Colombo, Bradley J. Monk et al. · JAMA Oncology · 2023 · 59 citations · Full text

Medicine, Oncology, Pharmacotherapy +14